Literature DB >> 25208819

The clinicopathological characteristics with long-term outcomes in malignant mesothelioma.

Mutlu Dogan1, Gungor Utkan, Cemil Hocazade, Dogan Uncu, Serife Toptas, Nuriye Ozdemir, Nurullah Zengin, Fikri Icli.   

Abstract

Malignant mesothelioma (MM) is a neoplasm which originates from serous membranes. It is relatively more common in Turkey. Ninety-nine patients between 2002-2009 were evaluated for survival and patient characteristics with chest pain, dyspnea, weight loss, loss of appetite, anemia, leukocytosis, thrombocytosis and lactate dehydrogenase (LDH) elevation, retrospectively. Male/female ratio was 1.41(58/41). Median age was 53(27-88). Asbestosis exposure rate was 78.5%. Most of the patients had better ECOG-PS (88.7% for 1-2). Chest pain (47.7%), dyspnea (44.8%), weight loss (49%), loss of appetite (50%), anemia (38%), leukocytosis (37.2%), thrombocytosis (26.6%) and LDH elevation (10.1%) were found with median values such as 11.8 g/dL (5-17.1) for hemoglobin, 8,800/mm3 for WBC (2,600-38,300), 382,000/mm(3) for platelets (28,000-1,504,000) and 253 IU/L for LDH (85-1,877), respectively. The most common site was pleura (62.3%). Half of the patients were unclassified, while epitheloid histopathology (39.4%) was most common in classified ones. RT rate was 42.1% in operated patients and all had pleural MM. Median OS was 22.9 months. Eighty percent of the patients had first-line CT with a clinical benefit rate of 63.3%. Second-line CT rate was 29% with a clinical benefit rate of 44%. Most preferred CT regimen was cisplatinum and pemetrexed. Most of the patients were male in their 50 s with pleural MM. They had chest pain, dyspnea, weight loss and loss of appetite as the most common symptoms at diagnosis. Only half of the patients could be subtyped with a predominance of epitheloid histology.

Entities:  

Mesh:

Year:  2014        PMID: 25208819     DOI: 10.1007/s12032-014-0232-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

1.  Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.

Authors:  Emin Tamer Elkiran; Mehmet Ali Kaplan; Alper Sevinc; Sercan Aksoy; Umut Demirci; Mesut Seker; Hakan Harputluoglu; Nuriye Yildirim Ozdemir; Feridun Isik; Arife Ulas; Mevlude Inanc; Ulku Yalcintas Arslan; Gamze Gokoz Dogu; Abdurrahman Isikdogan; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2012-06-22       Impact factor: 3.064

2.  Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.

Authors:  L M Krug; A J Wozniak; H L Kindler; R Feld; M Koczywas; J L Morero; C P Rodriguez; H J Ross; J E Bauman; S V Orlov; J C Ruckdeschel; A C Mita; L Fein; X He; R Hall; T Kawabe; S Sharma
Journal:  Lung Cancer       Date:  2014-07-05       Impact factor: 5.705

3.  A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Mehmet Ali Kaplan; Mehmet Küçüköner; Yilmaz Palanci; Osman Evliyaoglu; Cengizhan Sezgi; Hadice Sen; Ali İhsan Carkanat; Gokhan Kirbas
Journal:  Respiration       Date:  2010-09-28       Impact factor: 3.580

Review 4.  Malignant pleural mesothelioma: the standard of care and challenges for future management.

Authors:  Jan P van Meerbeeck; Arnaud Scherpereel; Veerle F Surmont; Paul Baas
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-13       Impact factor: 6.312

5.  Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey.

Authors:  S Emri; T Kocagoz; A Olut; Y Güngen; L Mutti; Y I Baris
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

Review 6.  Chemotherapy options and new advances in malignant pleural mesothelioma.

Authors:  J P C Steele; A Klabatsa
Journal:  Ann Oncol       Date:  2005-01-27       Impact factor: 32.976

7.  Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.

Authors:  A Umran Dogan; Y Izzettin Baris; Meral Dogan; Salih Emri; Ian Steele; Amira G Elmishad; Michele Carbone
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 8.  Epidemiology, biologic behavior, and natural history of mesothelioma.

Authors:  Lambros Zellos; David C Christiani
Journal:  Thorac Surg Clin       Date:  2004-11       Impact factor: 1.750

9.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

Review 10.  Malignant pleural mesothelioma.

Authors:  H L Kindler
Journal:  Curr Treat Options Oncol       Date:  2000-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.